Single-agent versus combination therapy for maintenance therapy in myeloma

Pieter Sonneveld, MD, PhD, Erasmus MC, Rotterdam, The Netherlands, discusses how single-agent maintenance therapy in multiple myeloma (MM) compares with more intensive regimens. Prof. Sonneveld notes that, although lenalidomide has been standard of care for years, combination therapies have shown favorable outcomes in the Phase III IsKia (NCT04483739) and PERSEUS (NCT03710603) trials, and lenalidomide plus daratumumab has the potential to become the new standard. This interview took place at the 12th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Видео Single-agent versus combination therapy for maintenance therapy in myeloma канала VJHemOnc – Video Journal of Hematology & HemOnc